MesoPher is a personalised DC therapy consisting of autologous DCs loaded with PheraLys, Amphera’s proprietary allogeneic lysate of mesothelioma cell lines. PheraLys, first developed for mesothelioma, contains a broad repertoire of tumour-associated antigens, many of which are also present in pancreatic cancer and other cancers.
Preclinical results showed that DCs loaded with mesothelioma cell lysate can induce T-cell immunity and reduce tumour growth in mice with pancreatic cancer. In mice with established pancreatic cancer (mimicking the situation of non-resected pancreatic cancer patients) synergistic anti-tumour effects were achieved when DC vaccination was combined with a CD40-agonist. The DC/αCD40 combination therapy was able to significantly delay tumour growth.
These exciting preclinical results were published in the Journal for ImmunoTherapy of Cancer (Link).